It is essential for clinicians to remain informed about ongoing clinical trials and the resulting data that may inform therapeutic strategies, affect clinical guidelines, expand treatment options, and ultimately improve patient quality of life.

The following clinical trials preview features seven US-based, Phase 2 and 3 clinical trials focusing on endometriosis or health issues related to endometriosis. Only one of the featured trials is currently not recruiting. The ranges of anticipated primary completion dates range from June 2026 through July 2029. The trials are arranged in order of their start date.

Quick View Table of Endometriosis Clinical Trials
Study TitlePhaseRecruiting?Estimated EnrollmentStart DateEstimated Primary Completion
Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital2No75January 2026December 2026
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain3Yes130December 2025August 2028
Glycemic Regulation as Endometriosis Adjunct Treatment (GREAT)2Yes14May 2025January 2027
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp (PREGnant)3Yes297March 2024June 2026
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis2Yes30February 2024June 2026
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis3Yes1000August 2023July 2029
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET /​ MRI2Yes24January 2023August 2026
Endometriosis Clinical Trials With Upcoming Completion Dates

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

  • Sponsor: Baylor College of Medicine
  • Goal: This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol [dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)] for e endometriosis-associated chronic pelvic pain (endo-CPP) with a 2:1 allocation ratio.
  • Interventions: Dronabinol capsules, placebo
  • Primary Outcome Measures: Pain intensity; Safety analysis.
  • Time Frames: Baseline to 8-weeks; Baseline to 8-weeks.
  • Study Details
  • Source

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

  • Sponsor: University of Michigan
  • Goal: The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
  • Intervention: Relugolix CT
  • Primary Outcome Measures: Change score in lipopolysaccharide (LPS)-stimulated Macrophage inflammatory protein-1 alpha (MIP1-α) levels; Change score for functional magnetic resonance imaging (fMRI) connectivity of the somatosensory cortices to the default-mode network.
  • Time Frames: Baseline and week 12 visit; Baseline and week 12 visit.
  • Study Details
  • Source

Glycemic Regulation as Endometriosis Adjunct Treatment (GREAT)

  • Sponsor: Boston Children's Hospital
  • Goal: The goal of this pilot trial is to learn if a novel non-hormonal treatment, metformin hydrochloride, works to treat pelvic pain in young women with endometriosis.
  • Interventions: Metformin Hydrochloride, placebo
  • Primary Outcome Measures: Change in pain assessed by the Brief Pain Inventory Interference Scale (BPI) over 6 months; Change in pain severity measured by Visual Analog Scale (VAS) over 6 months; Change in emotional functioning assessed by Beck Depression Inventory-II (BDI) over 6 months; Change in ratings of overall improvement assessed by the Patient Global Impression of Change scale (PGIC).
  • Time Frames: The same time frame applies to each primary outcome measure: Once at each of the three visits (at baseline, three months, six months).
  • Study Details
  • Source

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp (PREGnant)

  • Sponsor: Yale University
  • Goal: A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate.
  • Intervention: Elagolix 200 MG, Placebo or SOC IVF
  • Primary Outcome Measure: Live birth rate
  • Time Frame: Up to 15 months
  • Study Details
  • Source

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

  • Sponsor: Mclean Hospital
  • Goal: This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of treatment in patients with endometriosis. 
  • Interventions: Cannabidiol, placebo
  • Primary Outcome Measure: Visual analog scale.
  • Time Frame: 12 weeks.
  • Study Details
  • Source

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

  • Sponsor: Sumitomo Pharma Switzerland GmbH
  • Goal: The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
  • Interventions: Relugolix Combination Tablet
  • Primary Outcome Measures: Percent change from baseline in BMD (bone mineral density) at Month 48 on-treatment at lumbar spine (L1-L4) in women with uterine fibroids; Percent change from baseline in BMD at Month 48 on-treatment at lumbar spine (L1-L4) in women with endometriosis.
  • Time Frames: Baseline up to month 48; Baseline up to month 48.
  • Study Details
  • Source

Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET /​ MRI

  • Sponsor: University of North Caroline, Chapel Hill
  • Goal: The aim of this study is to assess the sensitivity and specificity of FFNP PET/MRI for diagnosis of endometriosis.
  • Intervention: 18F-fluorofuranylnorprogesterone PET / MRI 
  • Primary Outcome Measure: Sensitivity of 18F-fluorofuranylnorprogesterone (FFNP) PET/MR for evaluating endometriosis; Specificity of 18F-fluorofuranylnorprogesterone (FFNP) PET/MR for evaluating endometriosis.
  • Time Frame: Both primary outcome measures have the same time frame: Upon completion of all study image data collection for all participants [approximately 1 year].
  • Study Details
  • Source

Related Guidelines:

Sign up for alerts and stay informed on the latest published guidelines.

Copyright © 2026 Guideline Central, all rights reserved.